Publication
Greece
The applicable legislation establishing a national screening mechanism for foreign direct investments (FDI) and implementing Regulation (EU) 2019/452 in Greece is Law 5202/2025, which was adopted on 22 May 2025 (Greek FDI Law).
Canada | Publication | October 2023
Norton Rose Fulbright lawyers Kristin Wall, Randy Sutton, Veronique Barry, Christopher Guerreiro and Sarah Pennington contributed the Canada chapters to the Practical Law Life Sciences Global Guide on commercialization and regulation. The Guide is published in a Q&A format by Thomson Reuters, which is a leading global platform for trusted, up-to-date legal know how across all major practice areas.
Life Sciences Commercialisation in Canada: Overview
The Q&A Guide to life sciences commercialisation in Canada provides an overview of Canada’s life sciences sector, pricing and state funding, distribution and sale, importing, advertising, patents, trade marks, competition law, and product liability.
Life Sciences Regulation in Canada: Overview
The Q&A guide to life sciences regulation in Canada reviews the main legislation governing pharmaceuticals in Canada. The guide provides an overview of key practical issues, including clinical trials, manufacturing, marketing, abridged procedures, pharmacovigilance, data privacy, packaging and labelling, biological medicines, medical devices, health care IT, combination products, and natural health products.
Publication
The applicable legislation establishing a national screening mechanism for foreign direct investments (FDI) and implementing Regulation (EU) 2019/452 in Greece is Law 5202/2025, which was adopted on 22 May 2025 (Greek FDI Law).
Publication
Now in its third year, our Global M&A Trends and Risks report, published in partnership with Mergermarket, captures insights from senior dealmakers across the world on the key risks and opportunities shaping mergers and acquisitions (M&A) deal activity in 2025.
Subscribe and stay up to date with the latest legal news, information and events . . .
© Norton Rose Fulbright LLP 2025